Meeting
2024 ASCO Annual Meeting
Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer.
Presenter
Van K. Morris, MD
The University of Texas MD Anderson Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Rapid Oral Abstract Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Anal Cancer
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3513)
DOI
10.1200/JCO.2024.42.16_suppl.3513
Abstract #
3513
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Speaker: Arun Azad, PhD, MBBS, FRACP
Videos & Slides
2023 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA (ctDNA) for response assessment in patients with anal cancer treated with definitive chemoradiation.
Speaker: Janet Alvarez, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
A prospective validation cohort study of baseline plasma cell-free DNA (cfDNA) as a prognostic biomarker in newly diagnosed glioblastoma (GBM).
Speaker: Stephen Joseph Bagley, MD, MSCE
Speaker: Julie Vose, MD, MBA, FASCO